A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance

NCT05923281 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypercholesterolemia

Interventions

DRUG: K-877 0.2 mg/day (once daily)
DRUG: K-877 0.4 mg/day (once daily)
DRUG: Placebo (once daily)

Sponsor

Kowa Company, Ltd.